- ECHA
- Search for chemicals
- Adopted opinions and previous consultations on applications for authorisation
Adopted opinions and previous consultations on applications for authorisation
Adopted opinions and previous consultations on applications for authorisation
Adopted opinions and previous consultations on applications for authorisation
This page provides further information on the applications for authorisation or review reports, which have undergone consultation. The applications for authorisation are in the opinion development phase until the final opinions of the Committees for Risk Assessment and Socio-economic Analysis have been adopted and sent to the European Commission. Its decision-making process can be followed through the comitology register, where further information is published about the REACH Committee's past and upcoming meetings.
On 1 February 2020, the United Kingdom (UK) withdrew from the EU. The transition period provided by the withdrawal agreement ended on 31 December 2020. As of 1 January 2021, an application for an authorisation submitted by a person established in the UK (except Northern Ireland) is no longer valid in the EU, unless that application has been transferred to a legal entity established in the EU or Northern Ireland before the end of the transition period. Therefore, authorisation applications and decisions in so far as these concern persons established in the UK (except Northern Ireland) are no longer considered valid.
Related links
| 0225-01 | Initial | 4,4'-methylenebis[2-chloroaniline] | 202-918-9 | 101-14-4 | Limburgse Urethane Castings NV | Industrial use of 2,2'-Dichloro-4,4'-methylenedianiline (MOCA) in the manufacture of high-performance polyurethanes specifically for custom-made rollers with high reliability requirements for steel and aluminium sectors. | Commission decided | Details |
| 0184-01 | Initial | 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated | - | - | Lilly France S.A.S.; Eli Lilly Italia S.p.A. | Industrial formulation (dilution) of a silicone solution containing 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated and its subsequent use as a lubricant in the manufacture of medicinal product delivery devices | Commission decided | Details |
| 0085-01 | Initial | Bis(2-methoxyethyl) ether (Diglyme) | 203-924-4 | 111-96-6 | Life Technologies AS | Use of diglyme as a process chemical in the manufacture of Dynabeads. | Commission decided | Details |
| 0285-01 | Initial | Chromium trioxide | 215-607-8 | 1333-82-0 | Liebherr-Aerospace Lindenberg GmbH | Industrial use of chromium trioxide for functional chrome plating of actuation and landing gear systems for the aviation industry. | Opinions adopted | Details |
| 0285-02 | Initial | Chromium trioxide | 215-607-8 | 1333-82-0 | Liebherr-Aerospace Lindenberg GmbH | Industrial use of chromium trioxide for surface treatment of aluminium alloys for applications in the aerospace industries unrelated to functional chrome plating | Opinions adopted | Details |
| 0311-01 | Initial | Sodium dichromate | 234-190-3 | 10588-01-9 | Liebherr-Aerospace Lindenberg GmbH | Industrial use of sodium dichromate for the sealing after anodizing of aluminium alloys and passivation of metallic coatings of actuation and landing gear system parts for the aviation industry that meet the airworthiness certification requirements | Opinions adopted | Details |
| 0301-01 | Initial | Chromium trioxide | 215-607-8 | 1333-82-0 | LIBERTY GALATI SA [application transferred from original Applicant: "Liberty Liège Dudelange (BE)” due to a notified legal entity change] | Use of Chromium (VI) Trioxide and Sodium Dichromate for Passivation of Electrolytic Tinplate (ETP) | Opinions adopted | Details |
| 0301-02 | initial | Sodium dichromate | 234-190-3 | 10588-01-9 | LIBERTY GALATI SA [application transferred from original Applicant: "Liberty Liège Dudelange (BE)” due to a notified legal entity change] | Use of Chromium (VI) Trioxide and Sodium Dichromate for Passivation of Electrolytic Tinplate (ETP) | Opinions adopted | Details |
| 0176-01 | Initial | 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated | - | - | LFB BIOMEDICAMENTS | Use as virus inactivation into the manufacture process of plasma-derived immunoglobulins. | Commission decided | Details |
| 0226-01 | Initial | 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated | - | - | LETI Pharma, S.L.U. [name of applicant in the original application: Laboratorios LETI, S.L.U. updated due to a notified change of corporate name] | Use of 4-tert-OPnEO in aqueous buffers during the manufacturing process of the active pharmaceutical ingredient (Protein Q) of the veterinary vaccine LetiFend® | Commission decided | Details |